Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK makes landmark pricing agreement for rotavirus vaccine, Rotarix, for use with children living in humanitarian crises
GSK has committed to supply its rotavirus vaccine, Rotarix, through the Humanitarian Mechanism.
-
Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
The DSMB has recommended that the VIR-7831 arm of the trial be closed to enrolment while the data mature.
-
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021
16 sponsored abstracts from our diverse portfolio of innovative pipeline and licensed HIV treatment and prevention options will be presented
-
GSK receives CHMP positive opinion recommending approval of dostarlimab for women with recurrent or advanced endometrial cancer
This positive CHMP opinion brings us closer to providing dostarlimab as a new treatment option to women with endometrial cancer in Europe
-
GSK announces results evaluating its investigational monoclonal antibody, otilimab, for the treatment of hospitalised adult patients with COVID-19
GSK today announce results from the phase 2 proof of concept OSCAR study with otilimab, an investigational anti-GM-CSF monoclonal antibody.
-
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults.
-
GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
Companies to combine expertise in immunology and infectious diseases to accelerate development of promising new therapeutics for influenza.
-
GSK announces gender and diversity aspirational targets to increase representation at senior levels
Aspirational targets to increase ethnically diverse senior leadership in the US and UK.
-
GSK starts Phase III RSV candidate vaccine programme for older adults
Positive Phase I/II results established the robust immunogenicity of the vaccine candidate in the target population
-
GSK to sell Cephalosporin antibiotics business to Sandoz
GSK has announced it has reached an agreement with Sandoz, a Novartis division, to sell its Cephalosporin antibiotics business.
-
ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV
Fostemsavir addresses a critical need for those with little to no treatment options left who are at risk of further disease progression
-
GSK delivers FY 2020 reported sales of £34 billion, +1% AER, +3% CER and Adjusted EPS of 115.9p, -6% AER, -4% CER, in line with guidance; Total EPS 115.5p, +23% AER
Strong growth of new and specialty products; on track to deliver two exciting new companies
-
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
Companies aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use.
-
GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
The agreement recognises the track record and expertise of BBIL in developing and supplying vaccines against infectious diseases.
-
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19.
-
GSK ranks 1st in the 2021 Access to Medicine Index with leading R&D pipeline for priority diseases
Ranking reflects GSK leadership through access to its medicines and vaccines for people around the world.
-
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
The approval is based on the pivotal phase III ATLAS and FLAIR studies that included more than 1,100 patients from 16 countries.
-
GSK and Novartis announce collaboration to support scientific research into genetic diversity in Africa
Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years.
-
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium
Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
-
ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe
The EU Marketing Authorisation follows the US Food and Drug Administration (FDA) approval of Tivicay PD in 2020.
